nsc 338720 has been researched along with Neoplasms in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bowling, K; Chen, TL; Donehower, RC; Grochow, LB; Hartman, NR; O'Reilly, S; Rowinsky, EK; Struck, RF | 1 |
Bowman, A; Cummings, J; Dunlop, N; French, R; Jodrell, DI; MacLellan, A; Smyth, JF; Stewart, M | 1 |
Bowling, KM; Collins, J; Donehower, RC; Hartman, NR; O'Reilly, S; Rowinsky, EK; Strong, JM | 1 |
Alberti, D; Arzomanian, R; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Liu, G; Marnocha, R; Tutsch, KD; Van Ummersen, L; Wilding, G | 1 |
4 trial(s) available for nsc 338720 and Neoplasms
Article | Year |
---|---|
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Neoplasms; Picolines; Platelet Count | 1997 |
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Picolines; Treatment Failure; Vomiting | 1998 |
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Routes; Drug Administration Schedule; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Picolines | 2001 |
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Picolines | 2002 |